AI Article Synopsis
Article Abstract
A case of transient bullous dermolysis of the newborn is reported. A healthy Hispanic newborn developed bullae during the first two days of life. From age two to four weeks, the lesions healed with milia formation. There was no residual scarring or hypopigmentation. An induced blister showed dermal-epidermal separation with the PAS-positive basement membrane in the epidermal roof. PAS-positive inclusions were present in the cytoplasm of a few basal cells. Examination by electron microscopy showed degeneration of the collagen and anchoring fibrils. There were numerous stellate inclusions in the endoplasmic reticulum of the cytoplasm of the lesional basal keratinocytes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1600-0560.1991.tb01544.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comprehensive combined analysis of physician-initiated phase II and III clinical trials on a cultured human corneal endothelial cell product for treating bullous keratopathy.
Jpn J Ophthalmol
November 2024
Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Hirokoji-agaru, Kawaramachi-dori, Kamigyo-ku, Kyoto, 602-0841, Japan.
Article Synopsis
- A study evaluated the effectiveness and safety of cultured human corneal endothelial cells (cHCEC) for treating bullous keratopathy (BK) across phase II and III clinical trials involving 27 patients.
- The primary goal was to achieve a corneal endothelial cell density of at least 1000 cells/mm by 24 weeks post-transplant, which was successful in 94.1% of cases, alongside significant reductions in corneal thickness and improvements in vision.
- While 88.9% of patients experienced mild and temporary adverse events, the cHCEC treatment showed promising results in restoring corneal function and visual acuity.
Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review.
J Clin Aesthet Dermatol
July 2024
Drs. Kianfar, Dasdar, Marashi, Mahmoudi, and Daneshpazhooh are with the Autoimmune Bullous Diseases Research Center at Tehran University of Medical Sciences in Tehran, Iran.
Article Synopsis
- * Methods: Researchers conducted a thorough review of literature from various medical databases to gather relevant studies on RTX's effectiveness and safety for treating EBA.
- * Results: Out of 31 studies reviewed, RTX showed positive outcomes with a high clinical response (92.7%) and disease remission (73.8%), though a notable relapse rate (39.5%) was observed, with mild side effects experienced by some patients.
Self-improving dystrophic epidermolysis bullosa with a novel heterozygous missense variant in the COL7A1 gene in a Taiwanese family.
Wound Repair Regen
July 2024
Department of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Self-improving dystrophic epidermolysis bullosa (DEB) is a genodermatosis that is inherited autosomal dominantly or recessively, and its clinical symptoms may improve or subside spontaneously. Herein, we report a case of self-improving DEB with COL7A1 p.Gly2025Asp variant.
View Article and Find Full Text PDFSurgical Treatment of Bullous Exudative Retinal Detachment Secondary to Atypical Bilateral Central Serous Chorioretinopathy.
Turk J Ophthalmol
December 2023
Gazi University Faculty of Medicine, Department of Ophthalmology, Ankara, Türkiye
This study aimed to report the diagnostic process, treatment, and follow-up of a patient with bullous exudative retinal detachment (RD) associated with an atypical variant of bilateral central serous chorioretinopathy (CSCR). A 28-year-old woman was referred to our clinic for total bullous RD in the right eye with a vision level of light perception only. She had been previously diagnosed with idiopathic uveal effusion syndrome and treated with systemic corticosteroid therapy with no response, and was referred to us for scleral window surgery.
View Article and Find Full Text PDFNineteen-Month Immunity to Adverse Radiation Effects Following 5-Fraction Re-radiosurgery With 43.6 Gy for Local Progression After Prior 3-Fraction Radiosurgery for Brain Metastasis From Pan-Negative Lung Adenocarcinoma.
Cureus
October 2023
Department of Radiology, Aichi Medical University, Nagakute, JPN.
Clinical management of patients with local control failure following stereotactic radiosurgery (SRS) for brain metastasis (BM) can be frequently challenging. Re-irradiation with multi-fraction (fr) SRS by using a biological effective dose of ≥80 Gy, based on the linear-quadratic formula with an alpha/beta ratio of 10 (BED), can be an efficacious option for such a scenario with the BED of <80 Gy. However, its long-term safety beyond one year remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!